Prolonged survival after talc poudrage for malignant pleural mesothelioma: Case series

Respirology

Volumn 10, Issue 5, 2005, Pages 649-655

  Aelony, Yossef ^a,b   Yao, Janis F ^a  

^a KAISER PERMANENTE   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Malignant pleural effusion; Pleural diseases; Pleurodesis

Indexed keywords

ANTIBIOTIC AGENT; CEFALEXIN; DOXORUBICIN; MAGNESIUM SILICATE; TALC;

CANCER STAGING; CANCER SURVIVAL; CELLULITIS; CLINICAL ARTICLE; DYSPNEA; FEMALE; HEALTH CARE COST; HUMAN; LENGTH OF STAY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PLEURA MESOTHELIOMA; PLEURODESIS; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; THORACOSCOPIC TALC POUDRAGE; THORACOSCOPY; TREATMENT INDICATION; AGED; ARTICLE; MESOTHELIOMA; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PLEURA TUMOR; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL RATE; UNITED STATES;

AGED; CALIFORNIA; DYSPNEA; FEMALE; HUMANS; MALE; MESOTHELIOMA; NEOPLASM STAGING; PALLIATIVE CARE; PLEURAL NEOPLASMS; PLEURODESIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL RATE; TALC; THORACOSCOPY;

EID: 33644843963     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2005.00763.x     Document Type: Review

References (45)

1. Walker AM, Loughlin JE, Friedlander ER, Rothman KJ, Dreyer NA. Projections of asbestos-related disease 1980-2009. J. Occup. Med. 1983; 25: 409-25.
2. Baas P, Schouwink H, Zoetmulder FA. Malignant pleural mesothelioma. Ann. Oncol. 1998; 9: 139-49.
3. Chailleux E, Dabouis G, Pioche D et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 1988; 93: 159-62.
4. Fischbein A, Rohl A. Pleural mesothelioma and neighborhood asbestos exposure. Findings from microchemical analysis of lung tissue. JAMA 1984; 252: 86-7.
5. Law MR, Gregor A, Hodson ME, Bloom HJ, Turner-Warwick M. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 1984; 39: 255-9.
6. Hillardal G. Malignant mesothelioma 1982: review of 4710 published cases. Br. J. Dis. Chest 1983; 77: 321-43.
7. Antman KH, Blum RH, Greenberger JS. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am. J. Med. 1980; 68: 356-62.
8. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976; 31: 15-24.
9. Hunt KJ, Longton G, Williams MA, Livingston RB. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 1996; 109: 1239-42.
10. Metintas M, Özdemir N, Uçgun I et al. Cisplatin, mitomycin and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest 1999; 116: 391-8.
11. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 1999; 117: 54-65.
12. Vogelzang NJ, Schultz SM, Iannucci AM, Kennedy BJ. Malignant mesothelioma. The University of Minnesota experience. Cancer 1984; 53: 377-83.
13. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann. Thorac. Surg. 1999; 68: 1799-804.
14. Aelony Y. Survival with malignant pleural mesothelioma after talc poudrage. Am. Rev. Respir. Dis. 1991; 143: A662.
15. Aelony Y, King R, Boutin C. Thoracoscopic talc poudrage pleurodesis for chronic recurrent pleural effusions. Ann. Intern. Med. 1991; 115: 778-82.
16. Boutin C, Viallat JR, Aelony Y. Practical Thoracoscopy. Springer-Verlag, Berlin, 1991.
17. Aelony Y. Thoracoscopic talc pleurodesis (TTP) under local anesthesia. 10th World Congress for Bronchology and 10th World Congress for Bronchoesophagology, June 14-17, 1998: Budapest, Hungary. 1998; 141 (abstract).
18. Aelony Y, King RR, Boutin C. Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH. Chest 1998; 113: 1007-12.
19. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma. a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer 1993; 72: 389-93.
20. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma. a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer 1993; 72: 394-404.
21. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122-8.
22. Pass HI, Pogrebniak HW. Malignant pleural mesothelioma. Curr. Probl. Surg. 1993; 30: 921-1012.
23. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am. J. Clin. Oncol. 1990; 13: 4-9.
24. Linden CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Eur. Respir. J. 1996; 9: 2565-72.
25. Ruffie P, Feld R, Minkin S et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J. Clin. Oncol. 1989; 7: 1157-68.
26. Nasreen N, Mohammed KA, Dowling PA, Ward MJ, Galffy G, Antony VB. Talc induces apoptosis in human mesothelioma cells in vitro. Am. J. Respir. Crit. Care Med. 2000; 161: 595-600.
27. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions. An assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117: 73-8.
28. Sahn SA. Malignant pleural effusions. Clin. Chest Med. 1985; 6: 113-25.
29. Rodriguez-Panadero F, Lopez Mejias J. Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am. Rev. Respir. Dis. 1989; 139: 663-7.
30. Gottehrer A, Taryle DA, Reed CE, Sahn SA. Pleural fluid analysis in malignant mesothelioma. Prognostic implications. Chest 1991; 100: 1003-6.
31. Aelony Y, Yao J, King R. Pleural fluid pH as a predictive value for survival in epithelial malignant mesothelioma patients: a significant addition to staging procedures. Am. J. Respir. Crit. Care Med. 2003; 167/7: A902 (abstract).
32. Ginsberg RJ. Diffuse malignant mesothelioma: a therapeutic dilemma. Ann. Thorac. Surg. 1986; 42: 608.
33. Gore RB, Ducie CM, Luksza AR. Thirty years of mesothelioma in Barrow-in-Furness. Thorax 1998; 53: 21.
34. Rusch VW. The Grondin/Sugarbaker article reviewed. Oncology 1999; 13: 931-2.
35. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann. Intern. Med. 1982; 96: 746-55.
36. Shearin JC Jr, Jackson D. Malignant pleural mesothelioma. Report of 19 cases. J. Thorac. Cardiovasc. Surg. 1976; 71: 621-7.
37. DaValle MJ, Faber LP, Kittle CF, Jensik RJ. Extrapleural pneumonectomy for diffuse, malignant mesothelioma. Ann. Thorac. Surg. 1986; 42: 612-18.
38. Pisani RJ, Colby TV, Williams DE. Malignant mesothelioma of the pleura. Mayo Clin. Proc. 1988; 63: 1234-44.
39. Worn H. Chances and results of surgery of malignant mesothelioma of the pleura (author's transl). Thoraxchir. Vask. Chir. 1974; 22: 391-3 (in German).
40. Baldini EH, Recht A, Strauss GM et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. 1997; 63: 334-8.
41. Rice TW, Adelstein DJ, Kirby TJ et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. 1994; 58: 24-9.
42. Byrne JG, Karavas AN, Colson YL et al. Cardiac decortication (epicardiectomy) for occult constrictive cardiac physiology after left extrapleural pneumonectomy. Chest 2002; 122: 2256-9.
43. Muers MF, Rudd RM, O'Brien ME et al. BTS randomized feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 2004; 59: 144-8.
44. Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 1996; 110: 1387-93.
45. Canto A, Guijarro R, Arnau A, Galbis J, Martorell M, Garcia Aguado R. Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions. Thorac. Cardiovasc. Surg. 1997; 45: 16-19.